ZIVO Bioscience, Inc. (OTCQB: ZIVO), a leading biotech and agtech R&D company focused on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced positive preliminary results from a recent study. Conducted in collaboration with the University of Delaware, the study evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
The study demonstrated promising outcomes, showing that ZIVO’s unique algal-based ingredients may play a significant role in controlling the spread of LPAI, a viral infection that poses a serious risk to the poultry industry. These findings suggest the potential for ZIVO’s proprietary ingredients to be developed as effective interventions in the battle against avian influenza, a disease that can lead to significant economic losses in poultry farming.
Further research and development will be needed to fully assess the efficacy and potential applications of these ingredients in the field. However, the preliminary results indicate a promising path forward for ZIVO’s continued innovations in both the agricultural and health sectors.
Key Study Findings:
- Reduction in Viral Shedding: Birds treated with ZIVO’s proprietary ingredients showed a significant reduction in viral titers, meaning less virus was shed compared to untreated infected birds.
- Delayed Transmission: In a controlled environment where healthy chickens were exposed to infected birds, those receiving ZIVO’s products experienced a statistically significant delay in viral detection. This suggests that the products helped slow the spread of the disease by limiting viral replication in the host.
The study, conducted in two parts, demonstrated the efficacy of ZIVO’s active ingredients, which had previously been shown to help mitigate the effects of coccidiosis in broiler chickens.
In the first phase, infected birds that received the ZIVO treatment showed a notable decrease in viral titers early on, suggesting that the ingredients helped reduce the amount of detectable virus in the birds. While the viral reduction was not statistically significant at the end of the study, a numerical decline was still observed in treated birds.
The second phase of the study aimed to replicate a real-world, high-risk environment by housing healthy chickens with infected birds. Those receiving ZIVO’s active ingredients experienced a significant delay in viral detection, indicating that the products may slow viral replication, reducing the likelihood of disease transmission to other birds.
Implications for the Poultry Industry:
These favorable results suggest that ZIVO’s proprietary ingredients could serve as a valuable preventative measure for reducing the spread of avian influenza in commercial poultry operations. This could improve flock health, reduce the risk of outbreaks, and limit the need for vaccines, which often have limitations in preventing LPAI transmission.
The study tested multiple products to identify the most effective strategies for combating LPAI. While some products were better at lowering viral titers, others proved more effective at slowing disease spread. This suggests that combining different product formulations could offer more comprehensive protection against avian influenza.
Next Steps:
ZIVO is encouraged by these promising results and plans to continue research and development to further evaluate the efficacy of its products. As the need for effective solutions to combat avian influenza grows, ZIVO is confident that its proprietary feed ingredients can offer a viable alternative to traditional vaccines, providing a sustainable solution for poultry producers worldwide.
“We are excited by the outcomes of this study,” said John B. Payne, Chairman and CEO of ZIVO Bioscience. “The findings validate the potential of our products to reduce disease transmission, improve animal welfare, and support the sustainability of poultry production. We look forward to expanding our efforts to combat avian influenza and other viral challenges in the poultry industry.”
About ZIVO Bioscience:
ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio consisting of proprietary algal and bacterial strains, biologically active molecules, and production techniques. The company focuses on delivering innovative solutions for human and animal health, with applications in therapeutics, nutrition, and agriculture.
